Last reviewed · How we verify
Dexmedetomidin
Dexmedetomidin is a Small molecule drug developed by Children's Hospital Medical Center, Cincinnati. It is currently FDA-approved for Conscious sedation. Also known as: Group D, Medex inj, 200mcg/2ml, ILSUNG, sedadomid, precedex.
At a glance
| Generic name | Dexmedetomidin |
|---|---|
| Also known as | Group D, Medex inj, 200mcg/2ml, ILSUNG, sedadomid, precedex |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Target | Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Conscious sedation
Common side effects
- Hypotension
- Bradycardia
- Hypertension
- Nausea
- Fever
- Vomiting
- Atrial Fibrillation
- Hypoxia
- Dry Mouth
- Tachycardia
- Hemorrhage
- Anemia
Serious adverse events
- Hypotension Requiring Intervention
- Bradycardia Requiring Intervention
- Pulmonary Edema
- Ventricular Tachycardia
- Post-procedural Hemorrhage
- Atelectasis
- Hypovolemia
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial (PHASE4)
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
- The Effects of Dexmedetomidine on Postoperative Cognitive Function in Open Heart Surgery (NA)
- Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial) (PHASE2)
- PENG Block With Dexmedetomidine in Older Adults (NA)
- Comparison Between Total Intravenous Anesthesia With Magnesium Sulphate Versus Total Intravenous Anesthesia With Dexmedetomidine in Patients Undergoing Lumbar Spine Surgeries (PHASE3)
- Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidin CI brief — competitive landscape report
- Dexmedetomidin updates RSS · CI watch RSS
- Children's Hospital Medical Center, Cincinnati portfolio CI
Frequently asked questions about Dexmedetomidin
What is Dexmedetomidin?
Dexmedetomidin is a Small molecule drug developed by Children's Hospital Medical Center, Cincinnati, indicated for Conscious sedation.
What is Dexmedetomidin used for?
Dexmedetomidin is indicated for Conscious sedation.
Who makes Dexmedetomidin?
Dexmedetomidin is developed and marketed by Children's Hospital Medical Center, Cincinnati (see full Children's Hospital Medical Center, Cincinnati pipeline at /company/children-s-hospital-medical-center-cincinnati).
Is Dexmedetomidin also known as anything else?
Dexmedetomidin is also known as Group D, Medex inj, 200mcg/2ml, ILSUNG, sedadomid, precedex.
What development phase is Dexmedetomidin in?
Dexmedetomidin is FDA-approved (marketed).
What are the side effects of Dexmedetomidin?
Common side effects of Dexmedetomidin include Hypotension, Bradycardia, Hypertension, Nausea, Fever, Vomiting. Serious adverse events: Hypotension Requiring Intervention, Bradycardia Requiring Intervention, Pulmonary Edema, Ventricular Tachycardia.
What does Dexmedetomidin target?
Dexmedetomidin targets Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor.
Related
- Target: All drugs targeting Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor
- Manufacturer: Children's Hospital Medical Center, Cincinnati — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Conscious sedation
- Also known as: Group D, Medex inj, 200mcg/2ml, ILSUNG, sedadomid, precedex
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing